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Prolonged High-Dose Bivalirudin Infusion Reduces Major Bleeding
Without Increasing Stent Thrombosis in Patients Undergoing Primary
Percutaneous Coronary Intervention: Novel Insights From an Updated
Meta-Analysis
Gregor Fahrni, MD;* Mathias Wolfrum, MD;* Giovanni Luigi De Maria, MD; Adrian P. Banning, MD, MBBS; Umberto Benedetto, MD, PhD;
Rajesh K. Kharbanda, MD, PhD
Background-—The optimal antithrombotic therapy in patients with ST-segment-elevation myocardial infarction undergoing primary
percutaneous coronary intervention (PCI) remains a matter of debate. This updated meta-analysis investigated the impact of (1)
bivalirudin (with and without prolonged infusion) and (2) prolonged PCI-dose (1.75 mg/hg per hour) bivalirudin infusion compared
with conventional antithrombotic therapy on clinical outcomes in patients undergoing primary PCI.
Methods and Results-—Eligible randomized trials were searched throughMEDLINE, EMBASE, Cochrane database, and proceedings of
major congresses. Prespeciﬁed outcomes were major bleeding (thrombolysis in myocardial infarction major and Bleeding Academic
Research Consortium 3–5), acute stent thrombosis, as well as all-cause and cardiac mortality at 30 days. Six randomized trials
(n=17 294) were included. Bivalirudin compared with heparin (+/ glycoprotein-IIb/IIIa inhibitor) was associated with reduction in
major bleeding (odds ratio [OR]: 0.65, 95% CI: 0.48–0.88, P=0.006, derived from all 6 trials), increase in acute stent thrombosis (OR:
2.75, 95% CI: 1.46–5.18, P=0.002, 5 trials), and lower rate of all-causemortality (OR: 0.81, 95% CI: 0.67–0.98, P=0.03, 6 trials) as well
as cardiac mortality (OR: 0.69, 95% CI: 0.55–0.87, P=0.001, 5 trials). The incidence of acute stent thrombosis did not differ between
the prolonged PCI-dose bivalirudin and comparator group (OR: 0.81, 95% CI: 0.27–2.46, P=0.71, 3 trials), whereas the risk of bleeding
was reduced despite treatment with high-dose bivalirudin infusion (OR: 0.28, 95% CI: 0.13–0.60, P=0.001, 3 trials).
Conclusions-—Bivalirudin (with and without prolonged infusion) compared with conventional antithrombotic therapy in ST-segment-
elevation myocardial infarction patients undergoing primary PCI reduces major bleeding and death, but increases the rate of acute
stent thrombosis. However, prolonging the bivalirudin infusion at PCI-dose (1.75 mg/kg per hour) for 3 hours eliminates the
excess risk of acute stent thrombosis, while maintaining the bleeding beneﬁts. ( J Am Heart Assoc. 2016;5:e003515 doi:
10.1161/JAHA.116.003515)
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P rimary percutaneous coronary intervention (PCI) is nowstandard treatment for patients with an ST-segment-
elevation myocardial infarct (STEMI),1,2 signiﬁcantly reducing
major adverse cardiovascular events.3,4
Coronary artery plaque rupture initiates acute coronary
syndromes (ACS) by activating the coagulation cascade, and
adjunctive antiplatelet as well as antithrombotic therapy is
necessary to minimize peri- and postprocedural thrombotic
events.5–8 However, the use of these agents is frequently
associated with an increase of bleeding, which is itself
associated with a higher mortality.9–11
Unfractionated heparin (UFH) is the standard antithrom-
botic agent during PCI and in the setting of ACS.12
However, UFH has a number of limitations including the
need for anti-thrombin III as cofactor, and a highly variable
dose–response relation, resulting in a narrow therapeu-
tic window.13,14 These considerations have encouraged
investigations of alternative antithrombotic strategies. The
role of bivalirudin, a direct thrombin inhibitor, has been
investigated in 6 randomized trials in STEMI patients
undergoing primary PCI,15–20 but has resulted in conﬂicting
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evidence in terms of major bleeding, acute stent thrombo-
sis, and death.
A recently publishedmeta-analysis by Shah et al, comparing
bivalirudin with heparin in patients undergoing primary PCI,
demonstrated a signiﬁcant reduction in “protocol-deﬁned”
major bleeding and death in the bivalirudin group, but revealed
an increase in acute stent thrombosis.21 However, the impact of
a prolonged infusion of the short-acting bivalirudin on clinical
outcomes and the optimal dose of the prolonged bivalirudin
infusion (low dose at 0.25 mg/kg per hour versus PCI-dose at
1.75 mg/kg per hour) remains a matter of debate.
The aim of our updated meta-analysis was to investigate
the impact of bivalirudin compared with conventional
antithrombotic therapy on major bleeding (deﬁned as throm-
bolysis in myocardial infarction [TIMI] major and Bleeding
Academic Research Consortium [BARC] 3–5 bleeding), acute
stent thrombosis, and mortality in STEMI patients undergoing
primary PCI, and to assess whether prolonged bivalirudin
infusion at PCI-dose (1.75 mg/kg per hour) inﬂuences the
rate of acute stent thrombosis and major bleeding.
Methods
This review was guided by methods recommended by the
Cochrane Handbook for Systematic Reviews of Intervention22
and accomplished in compliance with the PRISMA (Preferred
Reporting Items for Systematic reviews and Meta-Analyses)
statement in healthcare interventions.23
Eligibility and Search Strategy
We considered data from all randomized controlled trials
comparing bivalirudin with heparin among STEMI patients
undergoing primary PCI.
Relevant studies were searched through MEDLINE, the
Cochrane database, the EMBASE database, as well as www.
clinicaltrials.gov, www.clinicaltrialresults.org, www.tctmd.com,
www.europcr.com, and www.acc.org websites until February
21, 2016 without language restrictions. In addition, prior meta-
analysis on the same topic as well as the reference lists of
included studies were reviewed to identify further citations. The
following key words were used: myocardial infarction and
bivalirudin.
Inclusion criteria for the meta-analysis comparing bivalir-
udin with conventional antithrombotic therapy were the
following: randomized treatment allocation, inclusion of STEMI
patients, and the intention to undergo PCI. Studies were
excluded if thrombolysis rather than PCI was used for
reperfusion treatment. For the subgroup analysis comparing
prolonged PCI-dose bivalirudin with heparin in STEMI patients,
we included only studies where administration of a prolonged
infusion at the higher dose of bivalirudin (1.75 mg/kg per
hour) was part of the protocol. The original authors obtained
institutional review committee approval and patient informed
consent for each included study.
Data Extraction and Validity Assessment
Two independent investigators (G.F. and M.W.) selected the
studies for inclusion, and any disagreements were resolved by
consensus with a third reviewer (R.K.K.). The data were
analyzed according to the intention-to-treat principle. The
original investigators were contacted to request relevant
missing data.
End-Point Selection
Selected end points were all-cause mortality, cardiac mortality,
and major bleeding at 30 days as well as acute stent
thrombosis for the analysis comparing bivalirudin versus
conventional antithrombotic therapy. Major bleeding at
30 days and acute stent thrombosis were the prespeciﬁed
outcome measurements for the subgroup analysis comparing
prolonged PCI-dose bivalirudin with conventional antithrom-
botic therapy. The prognostically more relevant TIMI major
bleeding24 (rather than the protocol-deﬁned non–coronary
artery bypass graft [CABG]–major bleeding) was considered in
the Harmonizing Outcomes with Revascularization and Stents
in Acute Myocardial Infarction (HORIZONS-AMI), Bavarian
Reperfusion Alternatives Evaluation 4 (BRAVE 4), and European
Ambulance Acute Coronary Syndrome Angiography (EURO-
MAX) trial; and BARC 3 to 5 bleeding was used in the How
Effective are Antithrombotic Therapies in Primary Percutaneous
Coronary Intervention (HEAT-PPCI), Bivalirudin in Acute
Myocardial Infarction versus Heparin and GPI Plus Heparin
(BRIGHT), and Minimizing Adverse Hemorrhagic Events by
Transradial Access Site and Systemic Implementation of Angiox
(MATRIX) trial (Table). Acute stent thrombosis was deﬁned
according to the Academic Research Consortium criteria.25
Statistical Analysis
Statistical analysis was performed by Review Manager, version
5.3 (The Nordic Cochrane Centre, Copenhagen, Denmark).
Odds ratios (OR) and 95% CI were used as summary statistics.
The statistical heterogeneity for each end point of interest was
assessed by using the Higgins I2 test.26 I2 values between 0%
and 30% and P>0.1 were considered not to be relevant,
according to the Cochrane guidelines.22 The ﬁxed-effect model
with the Mantel-Haenszel method was used to calculate the
summarized ORs. In case of relevant heterogeneity with an
I2>30% or P<0.1, we used the random effects model by
DerSimonian and Laird instead to calculate the pooled ORs.22
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Visual estimation of the funnel plot was used to assess potential
publication bias for each clinical outcome. P values were 2-
tailed, reaching statistical level of signiﬁcance at 0.05.
Results
Included Studies and Patient Population
The PRISMA statement ﬂowchart describes the process of the
literature screening, study selection, and reasons for exclu-
sion (Figure 1). Six hundred fourteen potentially relevant
citations were initially identiﬁed, of which 50 were retrieved to
assess in full-text. Eventually, results from 6 randomized trials
were eligible with a total of 17 294 patients included. Study
characteristics are highlighted in (Table). The funnel plots
suggest no relevant publication bias.
The BRIGHT trial enrolled patients presenting with a non-
STEMI; thus, since the outcome data were available sepa-
rately, we considered only results from the STEMI group.19 In
all studies, bivalirudin was given as initial bolus of 0.75 mg/
kg per hour followed by an infusion of 1.75 mg/kg per hour
during the procedure. The infusion at PCI-dose was continued
in all patients in the BRIGHT19 trial, as well as partly in the
EUROMAX16 and MATRIX20 trial, but was stopped immediately
after the intervention in the HORIZONS-AMI,15 HEAT-PPCI,18,
and BRAVE 4.17 Therefore, 3 studies were considered for the
subgroup analysis comparing prolonged PCI-dose bivalirudin
with heparin.
The mean age of the included patients was 62 years.
Seventy-seven percent were male and 18% had diabetes
mellitus. In this meta-analysis, more than 90% of participants
underwent PCI.
Table. Study Characteristics
Study Name (Ref)
HORIZONS-AMI15 EUROMAX16 BRAVE 417 HEAT-PPCI18 BRIGHT19 MATRIX20
Study design Multicenter,
open label
Multicenter,
open label
Multicenter,
open label
Single-center,
open label
Multicenter,
open label
Multicenter,
open label
Year of publication 2008 2013 2014 2014 2015 2015
Patients (n) ITT 3602 2198 544* 1812 1925† 7213‡
Age, y 60 62 61 63 57 65
Radial access (%) na 47 0 81 78 50
Clopidogrel (%) 96 51 97 with Heparin 11 100 38
Thienopyridine (%) 0 49 99 with Bivalirudin 89 0 55
Initial heparin bolus,
IU/kg
60 100 without GPI,
60 with GPI
70 to 100 70 100 without
GPI, 60
with GPI
70 to 100 without
GPI, 50 to 70
with GPI
Prolonged bivalirudin
infusion after PCI
(dose, n%, mean
duration)
Stopped
immediately
after PCI
1.75 mg/kg per
hour (22.5%),
0.25 mg/kg per
hour (77.5%),
4.5 hours
Stopped immediately
after PCI
Stopped
immediately
after PCI
1.75 mg/kg
per hour
(100%),
3 hours
1.75 mg/kg per
hour (34.4%),
0.25 mg/kg per
hour (59.0%),
6.2 hours
GPI use in bivalirudin
arm (%)
8 12 3 13 5 5
GPI use in heparin
arm (%)
98 69 6 15 6 and 100 26
Definition major
bleeding
TIMI major
bleeding§
at 30 days
TIMI major bleeding§
at 30 days
TIMI major bleeding§
at 30 days
BARC type
3 to 5k
at 28 days
BARC type
3 to 5k
at 30 days
BARC type 3 and 5k
at 30 days
BARC indicates Bleeding Academic Research Consortium; BRAVE 4, Bavarian Reperfusion Alternatives Evaluation 4; BRIGHT, Bivalirudin in Acute Myocardial Infarction versus Heparin and
GPI Plus Heparin; CABG, coronary artery bypass graft; EUROMAX, European Ambulance Acute Coronary Syndrome Angiography; GPI, glycoprotein IIb/IIIa inhibitors; HEAT-PPCI, How
Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention; HORIZONS-AMI, Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial
Infarction; ITT, intention-to-treat; MATRIX, Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox; na, not available; NSTEMI, non-ST-
segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction; TIMI, thrombolysis in myocardial infarction.
*Randomized to bivalirudin plus prasugrel and heparin plus clopidogrel but stopped early due to slow recruitment.
†Randomized to bivalirudin, heparin alone, and heparin plus GPI.
‡STEMI 56% and NSTEMI 44%.
§TIMI major bleeding: intracranial bleeding, overt bleeding with hemoglobin drop of >5 g/dL, fatal bleeding.
kBARC bleeding: Type 3: overt bleeding with hemoglobin drop of >3 g/dL or requiring transfusion, cardiac tamponade, bleeding requiring intervention or vasoactive agents, intracranial
bleeding; Type 4: CABG-related bleeding within 48 hours; Type 5: fatal bleeding.
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Clinical Outcome Comparing Bivalirudin Versus
Conventional Antithrombotic Therapy in STEMI
Patients
Major bleeding at 30 days
All 6 randomized trials contributed to the analysis of major
bleeding events, with 17 294 patients included (Figure 2A).
The rate of major bleeding was signiﬁcantly reduced in the
bivalirudin (1.92% or 160 of 8328) compared with the control
(2.93% or 263 of 8966) arm (OR: 0.65, 95% CI: 0.48–0.88,
P=0.006, heterogeneity P=0.10, I2=45%, random effects
model).
Acute stent thrombosis
Rate of stent thrombosis within 24 hours was reported in 5
studies involving a total of 16 750 patients (Figure 2B).
Signiﬁcant difference emerged between the 2 treatment
strategies: 75 of 8059 patients (0.93%) receiving bivalirudin
compared with 29 of 8691 (0.33%) receiving conventional
treatment had an acute thrombosis (OR: 2.75, 95% CI: 1.46–
5.18, P=0.002, heterogeneity P=0.14, I2=42%, random effects
model).
All-cause mortality at 30 days
All 6 randomized clinical trials, involving 17 294 patients,
provided data on overall death (Figure 2C).
The rate of death due to any cause was signiﬁcantly lower
in the bivalirudin (2.28% or 190 of 8328) compared with the
standard treatment group (2.74% or 246 of 8966) (OR: 0.81,
95% CI: 0.67–0.98, P=0.03, heterogeneity P=0.34, I2=11%,
ﬁxed effects model).
Cardiac mortality at 30 days
Cardiac death was assessed by 5 randomized trials involving
a total of 15 482 patients (Figure 2D). There were signiﬁ-
cantly fewer cardiac deaths with bivalirudin: 1.68% (125 of
Figure 1. Flow chart of the selection process as per PRISMA (Preferred Reporting Items for Systematic
reviews and Meta-Analysis) criteria. PCI indicates percutaneous coronary intervention; RCT, randomized
clinical trial; STEMI, ST-segment-elevation myocardial infarction.
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Figure 2. Forest plot of individual and summarized odds ratios for the comparison of bivalirudin vs heparin in STEMI patients for
(A) major bleeding at 30 days, (B) acute stent thrombosis, (C) all-cause mortality at 30 days, and (D) cardiac mortality at 30 days.
BRAVE 4, Bavarian Reperfusion Alternatives Evaluation 4; BRIGHT, Bivalirudin in Acute Myocardial Infarction versus Heparin and GPI
Plus Heparin; EUROMAX, European Ambulance Acute Coronary Syndrome Angiography; HEAT-PPCI, How Effective are
Antithrombotic Therapies in Primary Percutaneous Coronary Intervention; HORIZONS-AMI, Harmonizing Outcomes with
Revascularization and Stents in Acute Myocardial Infarction; MATRIX, Minimizing Adverse Hemorrhagic Events by Transradial
Access Site and Systemic Implementation of Angiox; M-H, Mantel-Haenszel; STEMI, ST-segment-elevation myocardial infarction.
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7423) compared with conventional treatment: 2.39% (193 of
8059), resulting in a 31% OR reduction (OR: 0.69, 95% CI:
0.55–0.87, P=0.001, heterogeneity P=0.75, I2=0%, ﬁxed
effects model).
Clinical Outcome Comparing Prolonged PCI-Dose
Bivalirudin Versus Conventional Antithrombotic
Therapy in STEMI Patients
Outcome data on acute stent thrombosis and major bleeding
in patients treated with extended high-dose bivalirudin
(1.75 mg/kg per hour) are available in 3 of the 6 randomized
clinical trials, involving 7337 patients.
Acute stent thrombosis and major bleeding at 30 days
The incidence of acute stent thrombosis did not differ in the
prolonged PCI-dose bivalirudin (0.26% or 4 of 1517) compared
with the standard (0.33% or 19 of 5820) treated arm (OR:
0.81, 95% CI: 0.27–2.46, P=0.71, heterogeneity P=0.64,
I2=0%, ﬁxed effects model) (Figure 3A).
The rate of major bleeding events was signiﬁcantly lower in
patient treated with prolonged PCI-dose bivalirudin (0.79% or 12
of 1517) compared with the controlled group (2.92% or 170 of
5820) (OR: 0.28, 95% CI: 0.13–0.60, P=0.001, heterogeneity
P=0.24, I2=30%, random effects model) (Figure 3B).
Discussion
The main ﬁndings from our meta-analysis are that bivalirudin
(with and without prolonged infusion) compared with conven-
tional antithrombotic therapy in patients undergoing primary
PCI reduces “prognostically relevant” major bleeding (TIMI
major and BARC 3–5) and death, but increases the rate of
acute stent thrombosis. However, prolonging the bivalirudin
infusion at the PCI-dose (1.75 mg/kg per hour) for 3 hours
after the coronary intervention eliminates the excess of acute
stent thrombosis, while maintaining the desired bleeding
beneﬁts.
Debate on Bleeding
The search for the ideal antithrombotic treatment to reduce
the rate of thrombotic complications, and minimize bleeding
in STEMI patients, was initiated by the HORIZONS-AMI trial.15
This multicenter trial involved 3602 patients with STEMI
undergoing primary PCI who were randomized to bivalirudin
alone or UFH plus routine use of glycoprotein IIb/IIIa inhibitor
(GPI). In the bivalirudin group, the rates of net adverse clinical
events (NACE) were signiﬁcantly reduced because of a lower
rate of major bleeding.
At this time, routine use of GPI in addition to heparin was
standard of care, and GPI was administered to more than 90%
A
B
Figure 3. Forest plot of individual and summarized odds ratios for the comparison of prolonged PCI dose bivalirudin vs heparin in STEMI
patients for (A) acute stent thrombosis and (B) major bleeding at 30 days. BRIGHT, Bivalirudin in Acute Myocardial Infarction versus
Heparin and GPI Plus Heparin; EUROMAX-ST, European Ambulance Acute Coronary Syndrome Angiography Stent thrombosis; MATRIX,
Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox; M-H, Mantel-Haenszel; PCI,
percutaneous coronary intervention; STEMI, ST-segment-elevation myocardial infarction.
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of patients presenting for primary PCI in Europe and the United
States.27,28 Previous randomized studies in patients with stable
angina, unstable angina, and non-STEMI showed a reduction in
bleeding complications with similar rates of ischemia after PCI
when bivalirudin was used instead of heparin plus GPI.29,30 This
formed the basis for the HORIZONS-AMI study. However, with
routine use of dual-antiplatelet therapy, the recommendation
to administer GPI in combination with heparin by default was no
longer considered as standard of care and the relevance of
HORIZONS-AMI on contemporary practice was uncertain.31
The EUROMAX trial compared bivalirudin versus heparin in
2218 STEMI patients.16 This time, the use of GPI was left to
the operator’s discretion. In addition, bivalirudin was contin-
ued for 4 hours post PCI (either in a low or a PCI-dose), and
radial access for PCI was used more often. There remained a
signiﬁcant reduction in protocol-deﬁned non-CABG major
bleeding with bivalirudin compared with heparin.
However, in the HORIZONS-AMI, BRAVE-4, and EUROMAX
trials, any blood product transfusion, even without overt
bleeding or signiﬁcant drop in hemoglobin, was deﬁned as
“non-CABG” major bleeding. In these trials, blood transfusions
accounted for a large proportion of primary end-point events,
though the relationship between transfusion and clinical
outcome remains unclear.32,33 The “prognostically more
relevant” TIMI major bleeding (fatal bleeding, intracranial
bleeding, or overt bleeding with drop of hemoglobin ≥5 g/dL)
was also reported in HORIZONS-AMI, BRAVE-4, and EURO-
MAX, but failed to reach statistical signiﬁcance in the BRAVE-
4 and EUROMAX trials.
The use of a nonstandardized “protocol-deﬁned” bleeding
deﬁnition in earlier ACS trials makes it difﬁcult to interpret
relative safety comparisons of different antithrombotic regi-
mens across studies, because results vary according to the
deﬁnitions used for bleeding. The Bleeding Academic Research
Consortium developed the BARC deﬁnitions for bleeding end
points, providing a consensus for bleeding end points.24
This limitation was addressed in the HEAT-PPCI study and
the BRIGHT studies, which enrolled patients during 2012 and
2013.18,19 HEAT-PPCI is a single-center trial that randomly
assigned STEMI patients to bivalirudin or UFH, with GPI
reserved for selective bailout use (deﬁned as evidence of
massive thrombus, slow- or no-reﬂow, or a thrombotic
complication). The multicenter BRIGHT trial randomized
patient into 3 study arms including bivalirudin alone, UFH
alone, and UFH plus GPI. As in HEAT-PPCI, GPI was reserved
only for bailout use in the ﬁrst 2 study arms. The frequency of
GPI use was similar within the study groups. HEAT-PPCI did
not demonstrate any difference in bleeding outcomes (BARC 2
and/or 3–5), whereas BRIGHT revealed only a superiority of
bivalirudin compared with heparin alone in terms of bleeding
requiring medical intervention (BARC 2–5), but not reaching
statistical signiﬁcance for major bleeding (BARC 3–5). PCI in
these later trials were largely performed by radial access,
which is associated with a lower rate of major bleeding.34
Therefore, it is possible that HEAT-PPCI and BRIGHT were
underpowered to detect a relevant difference in major
bleeding outcome.
The recently published MATRIX trial was designed to
address the impact of access route and prolonged bivalirudin
infusion.20 This multicenter trial randomized 7213 patients
with an ACS undergoing PCI to bivalirudin or UFH. Thereafter,
patients in the bivalirudin group were randomized to stop or
continue the infusion at the end of the procedure. The use of
GPI was left to the operator’s discretion. The study failed to
show a difference in the primary composite end point major
adverse cardiac event (MACE) (death, myocardial infarction,
or stroke) or NACE (major bleeding or major adverse cardiac
event) for the comparison between bivalirudin and UFH.
However, major bleeding (BARC 3–5) was signiﬁcantly lower
in the bivalirudin compared with the UFH group. This was
irrespective of the duration of the bivalirudin infusion.
Our meta-analysis that included all of these trials, involving
17 294 patients, shows a signiﬁcant reduction ofmajor bleeding
(TIMI major and BARC 3–5, rather than non-CABG major
bleeding) in patients treated with bivalirudin (1.92%) compared
with heparin (2.93%) (OR: 0.65, 95% CI: 0.48–0.88, P=0.006).
There is the concern that the imbalanced use of GPI in the
2 study groups may have an inﬂuence on bleeding outcome.
Two recent meta-analysis of over 25 000 patients undergoing
PCI for a range of indications (stable and unstable CAD) with
balanced use of GPI conﬁrmed a signiﬁcant reduction in major
bleeding with bivalirudin, suggesting that the beneﬁcial
effects on bleeding may be independent of GPI use.35,36
Debate on Stent Thrombosis
Reduction in bleeding is balanced by increased thrombotic
complications. The antithrombotic therapy in STEMI patients
undergoing primary PCI is especially important since this
population has an increased risk of stent thrombosis.37
The positive results of the HORIZONS-AMI trial in terms of
bleeding and mortality beneﬁt with bivalirudin were compro-
mised by an increase in stent thrombosis.15 Assignment to
bivalirudin, compared with UFH plus GPI, resulted in a 1.0%
absolute excess (1.3% versus 0.3%, P<0.001) of acute stent
thrombosis. This difference in stent thrombosis was present
within the ﬁrst 24 hours and no longer signiﬁcant at 30 days
(2.5% versus 1.9%, P=0.30) and 1 year (3.5% versus 3.1%,
P=0.53).38
This increase in early stent thrombosis may be caused by
residual thrombin activity after the discontinuation of the
short-acting bivalirudin at the end of the procedure and by
having low platelet inhibition with oral agents at this time of
transition.39
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Whether the rate of acute stent thrombosis could be
diminished by prehospital initiation of novel P2Y12 blockers
and prolonged infusion of bivalirudin at the end of the
procedure was assessed in the EUROMAX trial.16 However,
there remained an increased rate of acute stent thrombosis in
patients receiving bivalirudin compared with heparin (1.1%
versus 0.2%, P=0.007).
Dual antiplatelet therapy reduces the risk of stent throm-
bosis, and the potent third-generation P2Y12 inhibitors
prasugrel and ticagrelor have been shown to reduce stent
thrombosis in comparison with clopidogrel in STEMI patients
even more.40,41 However, recent data highlighted that even
for novel P2Y12 inhibitors, the time interval to achieve
maximal platelet inhibition is signiﬁcantly delayed in STEMI
patients, not reaching peak pharmacodynamic efﬁcacy for 4
to 6 hours,42,43 and nor does prasugrel and ticagrelor reduce
stent thrombosis in comparison to clopidogrel within the ﬁrst
24 hours.44,45 Therefore, unsurprisingly, given that oral
antiplatelets in EUROMAX were administered 50 minutes
(interquartile range 37–66) before the procedure, the patients
did not have P2Y12 blockade to prevent acute stent throm-
bosis, which occurred on average 2.3 hours (interquartile
range 1.8–2.8) after stent placement.46 Consequently, stop-
ping the short-lived and rapidly cleared bivalirudin immedi-
ately after stent placement compared to longer-acting heparin
should result in a substantial increase in acute stent
thrombosis, as seen in HEAT-PPCI.18
Extending the anticoagulation with bivalirudin during this
vulnerable window for stent thrombosis until the pharmaco-
dynamic effects of P2Y12 blockers become active seems
logical, but the exact dosage and duration still need to be
deﬁned.
In EUROMAX, all patients received prolonged bivalirudin
infusion after the procedure.16 However, only one ﬁfth were
treated at a PCI-dose of 1.75 mg/kg per hour bivalirudin,
whereas 80% receive a ﬁve times lower dose of 0.25 mg/kg
per hour. To the best of our knowledge, there are no data
showing that anticoagulation with bivalirudin at a dose of
0.25 mg/kg per hour is sufﬁcient to prevent thrombotic
complications, especially in a highly thrombotic milieu such as
during a myocardial infarction. A post-hoc analysis of the
EUROMAX trial revealed that a prolonged bivalirudin infusion
at a PCI-dose of 1.75 mg/kg per hour was associated with a
signiﬁcantly lower rate of acute stent thrombosis compared to
low-dose bivalirudin and carried the same risk for acute stent
thrombosis compared to heparin.46
The recently published MATRIX trial showed a borderline
increase in stent thrombosis in the bivalirudin group at
30 days (1.0% versus 0.6%, P=0.048).20 Moreover, there was
no difference in the rate of stent thrombosis when comparing
bivalirudin with a prolonged infusion to bivalirudin without a
prolonged infusion. However, this must be interpreted with
some reservation. Prolonged bivalirudin infusion at a PCI-dose
of 1.75 mg/kg per hour was given only to one third of
patients, whereas the rest received a low dose of 0.25 mg/kg
per hour.
The only randomized trial comparing bivalirudin with a
prolonged high-dose infusion (1.75 mg/kg per hour for
3 hours) to UFH was the BRIGHT trial.19 As the post-hoc
analysis of the EUROMAX trial had indicated,46 the BRIGHT
trial conﬁrmed that acute stent thrombosis was no more
common with bivalirudin followed by prolonged high-dose
infusion than heparin.
The results of our meta-analysis suggest that bivalirudin in
the overall study population is associated with an increase in
acute stent thrombosis compared to heparin (0.93% versus
0.33%, OR: 2.75, 95% CI: 1.46–5.18, P=0.002). However,
prolonging the bivalirudin infusion at the PCI-dose (1.75 mg/
kg per hour) for 3 hours eliminates the excess of acute stent
thrombosis (0.26% versus 0.33%, OR: 0.81, 95% CI: 0.27–
2.46, P=0.71), while maintaining the desired bleeding beneﬁts
(0.79% versus 2.92%, OR: 0.28, 95% CI: 0.13–0.60, P=0.001).
Debate on Death
In the HORIZONS-AMI trial, treatment with bivalirudin rather
than UFH plus GPI resulted in a signiﬁcantly lower rate of
death after primary PCI at 30 days.15 The robustness of this
ﬁnding has been questioned since it was a secondary ﬁnding
with a broad conﬁdence interval (95% CI=0.44–1.00, P=0.047)
and moreover, EUROMAX, BRAVE-4, HEAT-PPCI, and BRIGHT
failed to reach level of statistical signiﬁcance.16–19 However,
MATRIX provided further evidence of a reduction in mortality
when bivalirudin is compared to UFH.20
The consequences of acute stent thrombosis do not
appear to impact on the mortality advantage in STEMI
patients treated with bivalirudin. The effect on clinical
outcome of stent thrombosis that occurs after hospital
discharge in patients following elective coronary intervention
with well-preserved ventricular function might differ from
acute stent thrombosis that affects a recently infarcted
territory in patients closely monitored and with the possibility
of prompt coronary reintervention.
The relationship between major bleeding after PCI and
subsequent death has been conﬁrmed in several tri-
als.9,10,47,48 The precise mechanism remains unknown, but
the mortality beneﬁt seen with bivalirudin may reﬂect the
early prevention of hemorrhagic complications. Nevertheless,
HORIZONS-AMI showed a reduction in cardiac mortality not
only in bivalirudin-treated patients with major bleeding (5.8%
versus 14.6%, P=0.025), but also in those without major
bleeding (2.6% versus 3.8%, P=0.048).49 Therefore, prevention
of bleeding may only partly explain the lower death rate in the
bivalirudin group.
DOI: 10.1161/JAHA.116.003515 Journal of the American Heart Association 8
Prolonged Bivalirudin in Primary PCI Fahrni et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on January 25, 2019
Despite the initial higher rate of acute stent thrombosis,
treatment with bivalirudin rather than UFH was associated
with reduced rates of reinfarction (6.2% versus 8.2%,
P=0.04).50 Discontinuation of antiplatelet therapy to control
hemorrhage may increase the risk of reinfarction, including
subacute and late stent thrombosis,51–53 which is known to
be a major cause of subsequent death after primary PCI,54,55
and may partially explain this observation.
Our meta-analysis shows a signiﬁcant reduction in all-
cause mortality within 30 days in STEMI patients treated with
bivalirudin rather than with heparin (2.28% versus 2.74%, OR:
0.81, 95% CI: 0.67–0.98, P=0.03), which is even more
pronounced in cardiac death (1.68% versus 2.39%, OR: 0.69,
95% CI: 0.55–0.87, P=0.001).
Limitations
This meta-analysis has several limitations. Firstly, the
imbalanced use of GPI in the bivalirudin and heparin group
may have inﬂuenced the outcome. The Cochrane guidelines
do not recommend a meta-regression analysis on con-
founders if there are fewer than 10 trials in an analysis.22
However, previous meta-analysis comparing bivalirudin to
heparin with balanced GPI use in both groups including
more than 25 000 patients undergoing PCI for stable
coronary artery disease and ACS showed a signiﬁcant
bleeding beneﬁt in the bivalirudin group.35,36 Secondly,
variation in protocol-deﬁned major bleedings among the
included studies makes a direct comparison difﬁcult. Thus,
we used the prognostically more relevant TIMI major
bleeding (rather than the protocol-deﬁned non-CABG major
bleeding) for HORIZONS-AMI, EUROMAX, and BRAVE-4 and
the recommended BARC 3–5 major bleeding for HEAT-PPCI,
BRIGHT, and MATRIX.25 This ensures that the bleeding
outcome in our meta-analysis is clinically relevant. Thirdly,
despite contacting the original investigators, the rates of
cardiac death from HEAT-PPCI were not available.18 How-
ever, calculating the summarized OR with a random effect
model, assuming that all deaths are caused by cardiac
mortality, still resulted in a signiﬁcant difference in favor of
bivalirudin. Fourthly, the MATRIX trial also included non-
STEMI patients and outcome for STEMI patients is not
available separately.20 However, this non-STEMI population
contributes only 18.5% of the whole study population in our
meta-analysis, and the rate of acute stent thrombosis in the
MATRIX trial treated with prolonged PCI-dose bivalirudin
coincides with the results of the BRIGHT STEMI population,
in which all received a prolonged PCI-dose bivalirudin
infusion. Therefore, we believe that this is unlikely to have
a relevant impact on our overall ﬁndings. Fifthly, the
bivalirudin infusion at PCI-dose (1.75 mg/kg per hour) was
continued in all patients in the BRIGHT trial.19 However,
prolonging the infusion at the higher dose, rather than a
lower dose (0.25 mg/kg per hour), was left to the
operators’ discretion in the EUROMAX and MATRIX tri-
als.16,20 Consequently, data for the subgroup analysis are in
part not randomized. Nevertheless, these are the best data
available to answer this remaining important question.
Conclusions
Bivalirudin (with and without prolonged infusion) compared
with conventional therapy in STEMI patients undergoing
primary PCI reduces major bleeding (TIMI major and BARC
3–5) and death, but increases the risk of acute stent
thrombosis. However, prolonging the bivalirudin infusion at
a PCI-dose (1.75 mg/kg per hour) for 3 hours eliminates the
excess of acute stent thrombosis, while maintaining the
bleeding beneﬁts.
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